PMC:7205724 / 10726-11458 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"353","span":{"begin":392,"end":395},"obj":"Gene"},{"id":"354","span":{"begin":234,"end":242},"obj":"Species"},{"id":"355","span":{"begin":318,"end":326},"obj":"Species"},{"id":"356","span":{"begin":457,"end":465},"obj":"Species"},{"id":"357","span":{"begin":475,"end":484},"obj":"Species"},{"id":"358","span":{"begin":547,"end":556},"obj":"Species"},{"id":"359","span":{"begin":255,"end":263},"obj":"Disease"}],"attributes":[{"id":"A353","pred":"tao:has_database_id","subj":"353","obj":"Gene:1401"},{"id":"A354","pred":"tao:has_database_id","subj":"354","obj":"Tax:9606"},{"id":"A355","pred":"tao:has_database_id","subj":"355","obj":"Tax:9606"},{"id":"A356","pred":"tao:has_database_id","subj":"356","obj":"Tax:9606"},{"id":"A357","pred":"tao:has_database_id","subj":"357","obj":"Tax:2697049"},{"id":"A358","pred":"tao:has_database_id","subj":"358","obj":"Tax:2697049"},{"id":"A359","pred":"tao:has_database_id","subj":"359","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T75","span":{"begin":83,"end":89},"obj":"Body_part"},{"id":"T76","span":{"begin":103,"end":111},"obj":"Body_part"},{"id":"T77","span":{"begin":357,"end":367},"obj":"Body_part"},{"id":"T78","span":{"begin":435,"end":441},"obj":"Body_part"},{"id":"T79","span":{"begin":485,"end":488},"obj":"Body_part"},{"id":"T80","span":{"begin":533,"end":539},"obj":"Body_part"},{"id":"T81","span":{"begin":619,"end":625},"obj":"Body_part"},{"id":"T82","span":{"begin":725,"end":731},"obj":"Body_part"}],"attributes":[{"id":"A75","pred":"fma_id","subj":"T75","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A76","pred":"fma_id","subj":"T76","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A77","pred":"fma_id","subj":"T77","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A78","pred":"fma_id","subj":"T78","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A79","pred":"fma_id","subj":"T79","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A80","pred":"fma_id","subj":"T80","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A81","pred":"fma_id","subj":"T81","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A82","pred":"fma_id","subj":"T82","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T67","span":{"begin":255,"end":263},"obj":"Disease"},{"id":"T68","span":{"begin":475,"end":479},"obj":"Disease"},{"id":"T69","span":{"begin":547,"end":551},"obj":"Disease"}],"attributes":[{"id":"A67","pred":"mondo_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A68","pred":"mondo_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A69","pred":"mondo_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T113","span":{"begin":0,"end":1},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T114","span":{"begin":15,"end":17},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T115","span":{"begin":28,"end":31},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T116","span":{"begin":83,"end":89},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T117","span":{"begin":230,"end":233},"obj":"http://purl.obolibrary.org/obo/CLO_0050884"},{"id":"T118","span":{"begin":314,"end":317},"obj":"http://purl.obolibrary.org/obo/CLO_0050884"},{"id":"T119","span":{"begin":378,"end":379},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T120","span":{"begin":435,"end":441},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T121","span":{"begin":533,"end":539},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T122","span":{"begin":619,"end":625},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T123","span":{"begin":725,"end":731},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T121","span":{"begin":159,"end":176},"obj":"Chemical"}],"attributes":[{"id":"A121","pred":"chebi_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T6","span":{"begin":32,"end":44},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"},{"id":"T7","span":{"begin":357,"end":373},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A7","pred":"meddra_id","subj":"T7","obj":"http://purl.bioontology.org/ontology/MEDDRA/10025251"},{"id":"A6","pred":"meddra_id","subj":"T6","obj":"http://purl.bioontology.org/ontology/MEDDRA/10062026"}],"text":"A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T82","span":{"begin":485,"end":488},"obj":"Chemical"}],"attributes":[{"id":"A82","pred":"chebi_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/CHEBI_33697"}],"text":"A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T82","span":{"begin":255,"end":263},"obj":"Species"},{"id":"T83","span":{"begin":475,"end":484},"obj":"Species"},{"id":"T84","span":{"begin":547,"end":556},"obj":"Species"}],"attributes":[{"id":"A82","pred":"ncbi_taxonomy_id","subj":"T82","obj":"NCBItxid:2697049"},{"id":"A83","pred":"ncbi_taxonomy_id","subj":"T83","obj":"NCBItxid:2697049"},{"id":"A84","pred":"ncbi_taxonomy_id","subj":"T84","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T92","span":{"begin":0,"end":264},"obj":"Sentence"},{"id":"T93","span":{"begin":265,"end":396},"obj":"Sentence"},{"id":"T94","span":{"begin":397,"end":566},"obj":"Sentence"},{"id":"T95","span":{"begin":567,"end":732},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"354","span":{"begin":234,"end":242},"obj":"Species"},{"id":"359","span":{"begin":255,"end":263},"obj":"Disease"},{"id":"355","span":{"begin":318,"end":326},"obj":"Species"},{"id":"353","span":{"begin":392,"end":395},"obj":"Gene"},{"id":"356","span":{"begin":457,"end":465},"obj":"Species"},{"id":"357","span":{"begin":475,"end":484},"obj":"Species"},{"id":"358","span":{"begin":547,"end":556},"obj":"Species"}],"attributes":[{"id":"A357","pred":"pubann:denotes","subj":"357","obj":"Tax:2697049"},{"id":"A355","pred":"pubann:denotes","subj":"355","obj":"Tax:9606"},{"id":"A353","pred":"pubann:denotes","subj":"353","obj":"Gene:1401"},{"id":"A354","pred":"pubann:denotes","subj":"354","obj":"Tax:9606"},{"id":"A359","pred":"pubann:denotes","subj":"359","obj":"MESH:C000657245"},{"id":"A358","pred":"pubann:denotes","subj":"358","obj":"Tax:2697049"},{"id":"A356","pred":"pubann:denotes","subj":"356","obj":"Tax:9606"}],"text":"A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T1222","span":{"begin":392,"end":395},"obj":"Protein"}],"attributes":[{"id":"A1222","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/Q5U0J2"},{"id":"A1223","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/Q07203"},{"id":"A1224","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/Q01687"},{"id":"A1225","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/P97315"},{"id":"A1226","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/P67967"},{"id":"A1227","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/P67966"},{"id":"A1228","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/P47875"},{"id":"A1229","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/P32965"},{"id":"A1230","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/P21291"},{"id":"A1231","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/P08462"},{"id":"A1232","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/A8K268"}],"text":"A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T94687","span":{"begin":0,"end":1},"obj":"DT"},{"id":"T22655","span":{"begin":2,"end":7},"obj":"NN"},{"id":"T19573","span":{"begin":8,"end":13},"obj":"NN"},{"id":"T23972","span":{"begin":14,"end":15},"obj":"-LRB-"},{"id":"T55337","span":{"begin":15,"end":17},"obj":"CD"},{"id":"T96728","span":{"begin":17,"end":18},"obj":"-RRB-"},{"id":"T92410","span":{"begin":19,"end":27},"obj":"RB"},{"id":"T26265","span":{"begin":28,"end":31},"obj":"VBZ"},{"id":"T35997","span":{"begin":32,"end":44},"obj":"VBN"},{"id":"T92380","span":{"begin":45,"end":48},"obj":"DT"},{"id":"T38590","span":{"begin":49,"end":55},"obj":"NN"},{"id":"T37156","span":{"begin":56,"end":59},"obj":"CC"},{"id":"T24661","span":{"begin":60,"end":66},"obj":"NN"},{"id":"T94632","span":{"begin":67,"end":69},"obj":"IN"},{"id":"T56352","span":{"begin":70,"end":82},"obj":"JJ"},{"id":"T65134","span":{"begin":83,"end":89},"obj":"NN"},{"id":"T64844","span":{"begin":90,"end":94},"obj":"WDT"},{"id":"T95987","span":{"begin":95,"end":102},"obj":"VBP"},{"id":"T86655","span":{"begin":103,"end":111},"obj":"NN"},{"id":"T45118","span":{"begin":112,"end":118},"obj":"NNS"},{"id":"T26321","span":{"begin":119,"end":125},"obj":"JJR"},{"id":"T17226","span":{"begin":126,"end":130},"obj":"IN"},{"id":"T2522","span":{"begin":131,"end":132},"obj":"CD"},{"id":"T48589","span":{"begin":132,"end":133},"obj":"-COLON-"},{"id":"T90182","span":{"begin":133,"end":136},"obj":"CD"},{"id":"T89317","span":{"begin":137,"end":145},"obj":"VBN"},{"id":"T28925","span":{"begin":146,"end":150},"obj":"IN"},{"id":"T68950","span":{"begin":151,"end":158},"obj":"JJ"},{"id":"T58621","span":{"begin":159,"end":169},"obj":"JJ"},{"id":"T22929","span":{"begin":170,"end":176},"obj":"NNS"},{"id":"T50644","span":{"begin":177,"end":180},"obj":"CC"},{"id":"T63224","span":{"begin":181,"end":189},"obj":"JJ"},{"id":"T22041","span":{"begin":190,"end":200},"obj":"JJ"},{"id":"T89053","span":{"begin":201,"end":205},"obj":"NN"},{"id":"T94835","span":{"begin":206,"end":208},"obj":"IN"},{"id":"T20257","span":{"begin":209,"end":217},"obj":"JJ"},{"id":"T49329","span":{"begin":218,"end":226},"obj":"NNS"},{"id":"T91601","span":{"begin":227,"end":229},"obj":"IN"},{"id":"T6238","span":{"begin":230,"end":233},"obj":"CD"},{"id":"T3048","span":{"begin":234,"end":242},"obj":"NNS"},{"id":"T18696","span":{"begin":243,"end":247},"obj":"IN"},{"id":"T93206","span":{"begin":248,"end":254},"obj":"JJ"},{"id":"T71443","span":{"begin":255,"end":263},"obj":"NN"},{"id":"T46997","span":{"begin":265,"end":268},"obj":"DT"},{"id":"T7672","span":{"begin":269,"end":274},"obj":"NN"},{"id":"T83098","span":{"begin":275,"end":281},"obj":"VBD"},{"id":"T5017","span":{"begin":282,"end":290},"obj":"JJ"},{"id":"T96870","span":{"begin":291,"end":302},"obj":"NN"},{"id":"T42442","span":{"begin":303,"end":305},"obj":"IN"},{"id":"T61149","span":{"begin":306,"end":309},"obj":"PDT"},{"id":"T89276","span":{"begin":310,"end":313},"obj":"DT"},{"id":"T53728","span":{"begin":314,"end":317},"obj":"CD"},{"id":"T50396","span":{"begin":318,"end":326},"obj":"NNS"},{"id":"T59179","span":{"begin":327,"end":338},"obj":"VBN"},{"id":"T83510","span":{"begin":339,"end":341},"obj":"IN"},{"id":"T2183","span":{"begin":342,"end":344},"obj":"DT"},{"id":"T4240","span":{"begin":345,"end":353},"obj":"NN"},{"id":"T18383","span":{"begin":354,"end":356},"obj":"IN"},{"id":"T99269","span":{"begin":357,"end":367},"obj":"NN"},{"id":"T12131","span":{"begin":368,"end":373},"obj":"NN"},{"id":"T36613","span":{"begin":374,"end":377},"obj":"CC"},{"id":"T91622","span":{"begin":378,"end":379},"obj":"DT"},{"id":"T39579","span":{"begin":380,"end":388},"obj":"NN"},{"id":"T72559","span":{"begin":389,"end":391},"obj":"IN"},{"id":"T31686","span":{"begin":392,"end":395},"obj":"NN"},{"id":"T20580","span":{"begin":397,"end":406},"obj":"VBG"},{"id":"T23341","span":{"begin":407,"end":418},"obj":"NN"},{"id":"T23846","span":{"begin":419,"end":421},"obj":"IN"},{"id":"T23496","span":{"begin":422,"end":434},"obj":"JJ"},{"id":"T68740","span":{"begin":435,"end":441},"obj":"NN"},{"id":"T74721","span":{"begin":441,"end":442},"obj":"-COMMA-"},{"id":"T3255","span":{"begin":443,"end":446},"obj":"PDT"},{"id":"T47829","span":{"begin":447,"end":450},"obj":"DT"},{"id":"T16466","span":{"begin":451,"end":456},"obj":"CD"},{"id":"T26913","span":{"begin":457,"end":465},"obj":"NNS"},{"id":"T47643","span":{"begin":466,"end":469},"obj":"WP"},{"id":"T10299","span":{"begin":470,"end":474},"obj":"VBD"},{"id":"T19318","span":{"begin":475,"end":484},"obj":"NN"},{"id":"T2642","span":{"begin":485,"end":488},"obj":"NN"},{"id":"T76428","span":{"begin":489,"end":497},"obj":"JJ"},{"id":"T59448","span":{"begin":498,"end":504},"obj":"IN"},{"id":"T49967","span":{"begin":505,"end":516},"obj":"NN"},{"id":"T2352","span":{"begin":517,"end":519},"obj":"IN"},{"id":"T3020","span":{"begin":520,"end":532},"obj":"JJ"},{"id":"T57517","span":{"begin":533,"end":539},"obj":"NN"},{"id":"T55829","span":{"begin":540,"end":546},"obj":"VBD"},{"id":"T39392","span":{"begin":547,"end":556},"obj":"NN"},{"id":"T26456","span":{"begin":557,"end":565},"obj":"JJ"},{"id":"T52249","span":{"begin":567,"end":572},"obj":"EX"},{"id":"T13795","span":{"begin":573,"end":577},"obj":"VBD"},{"id":"T15563","span":{"begin":578,"end":580},"obj":"DT"},{"id":"T53693","span":{"begin":581,"end":588},"obj":"NN"},{"id":"T35357","span":{"begin":589,"end":595},"obj":"NNS"},{"id":"T16756","span":{"begin":596,"end":605},"obj":"VBG"},{"id":"T53621","span":{"begin":606,"end":618},"obj":"JJ"},{"id":"T81904","span":{"begin":619,"end":625},"obj":"NN"},{"id":"T11852","span":{"begin":626,"end":631},"obj":"RB"},{"id":"T58859","span":{"begin":632,"end":634},"obj":"CC"},{"id":"T35171","span":{"begin":635,"end":643},"obj":"JJ"},{"id":"T39367","span":{"begin":644,"end":651},"obj":"NN"},{"id":"T20306","span":{"begin":652,"end":659},"obj":"IN"},{"id":"T63670","span":{"begin":660,"end":672},"obj":"JJ"},{"id":"T44856","span":{"begin":673,"end":680},"obj":"NN"},{"id":"T15733","span":{"begin":681,"end":683},"obj":"TO"},{"id":"T71428","span":{"begin":684,"end":692},"obj":"VB"},{"id":"T29390","span":{"begin":693,"end":696},"obj":"DT"},{"id":"T54708","span":{"begin":697,"end":701},"obj":"JJ"},{"id":"T64138","span":{"begin":702,"end":708},"obj":"NN"},{"id":"T21425","span":{"begin":709,"end":711},"obj":"IN"},{"id":"T75685","span":{"begin":712,"end":724},"obj":"JJ"},{"id":"T78861","span":{"begin":725,"end":731},"obj":"NN"}],"relations":[{"id":"R32394","pred":"arg1Of","subj":"T22929","obj":"T58621"},{"id":"R12539","pred":"arg1Of","subj":"T22929","obj":"T50644"},{"id":"R32883","pred":"arg2Of","subj":"T89053","obj":"T50644"},{"id":"R99734","pred":"arg1Of","subj":"T89053","obj":"T63224"},{"id":"R84751","pred":"arg1Of","subj":"T89053","obj":"T22041"},{"id":"R58957","pred":"arg1Of","subj":"T48589","obj":"T94835"},{"id":"R75573","pred":"arg2Of","subj":"T49329","obj":"T94835"},{"id":"R52082","pred":"arg1Of","subj":"T19573","obj":"T94687"},{"id":"R65194","pred":"arg1Of","subj":"T19573","obj":"T22655"},{"id":"R95106","pred":"arg1Of","subj":"T19573","obj":"T23972"},{"id":"R42168","pred":"arg2Of","subj":"T55337","obj":"T23972"},{"id":"R95339","pred":"arg3Of","subj":"T96728","obj":"T23972"},{"id":"R78448","pred":"arg1Of","subj":"T35997","obj":"T92410"},{"id":"R65706","pred":"arg1Of","subj":"T19573","obj":"T26265"},{"id":"R73941","pred":"arg2Of","subj":"T35997","obj":"T26265"},{"id":"R20951","pred":"arg1Of","subj":"T19573","obj":"T35997"},{"id":"R83087","pred":"arg2Of","subj":"T37156","obj":"T35997"},{"id":"R97536","pred":"arg1Of","subj":"T37156","obj":"T92380"},{"id":"R32731","pred":"arg1Of","subj":"T38590","obj":"T37156"},{"id":"R69272","pred":"arg2Of","subj":"T24661","obj":"T37156"},{"id":"R40627","pred":"arg1Of","subj":"T37156","obj":"T94632"},{"id":"R73729","pred":"arg2Of","subj":"T65134","obj":"T94632"},{"id":"R7895","pred":"arg1Of","subj":"T65134","obj":"T56352"},{"id":"R7377","pred":"arg1Of","subj":"T37156","obj":"T64844"},{"id":"R67249","pred":"arg1Of","subj":"T37156","obj":"T95987"},{"id":"R70225","pred":"arg2Of","subj":"T45118","obj":"T95987"},{"id":"R10830","pred":"arg1Of","subj":"T45118","obj":"T86655"},{"id":"R61261","pred":"arg1Of","subj":"T45118","obj":"T26321"},{"id":"R50969","pred":"arg1Of","subj":"T26321","obj":"T17226"},{"id":"R4008","pred":"arg2Of","subj":"T48589","obj":"T17226"},{"id":"R30054","pred":"arg1Of","subj":"T2522","obj":"T48589"},{"id":"R45762","pred":"arg2Of","subj":"T90182","obj":"T48589"},{"id":"R9970","pred":"arg2Of","subj":"T48589","obj":"T89317"},{"id":"R87348","pred":"arg1Of","subj":"T89317","obj":"T28925"},{"id":"R60332","pred":"arg2Of","subj":"T50644","obj":"T28925"},{"id":"R69387","pred":"arg1Of","subj":"T22929","obj":"T68950"},{"id":"R98484","pred":"arg1Of","subj":"T49329","obj":"T20257"},{"id":"R34116","pred":"arg1Of","subj":"T49329","obj":"T91601"},{"id":"R5522","pred":"arg2Of","subj":"T3048","obj":"T91601"},{"id":"R74118","pred":"arg1Of","subj":"T3048","obj":"T6238"},{"id":"R51409","pred":"arg1Of","subj":"T3048","obj":"T18696"},{"id":"R40479","pred":"arg2Of","subj":"T71443","obj":"T18696"},{"id":"R90019","pred":"arg1Of","subj":"T71443","obj":"T93206"},{"id":"R55615","pred":"arg1Of","subj":"T7672","obj":"T46997"},{"id":"R40867","pred":"arg1Of","subj":"T7672","obj":"T83098"},{"id":"R64658","pred":"arg2Of","subj":"T96870","obj":"T83098"},{"id":"R66056","pred":"arg1Of","subj":"T96870","obj":"T5017"},{"id":"R52864","pred":"arg1Of","subj":"T96870","obj":"T42442"},{"id":"R70060","pred":"arg2Of","subj":"T50396","obj":"T42442"},{"id":"R51479","pred":"arg1Of","subj":"T50396","obj":"T61149"},{"id":"R50628","pred":"arg1Of","subj":"T50396","obj":"T89276"},{"id":"R30895","pred":"arg1Of","subj":"T50396","obj":"T53728"},{"id":"R56320","pred":"arg1Of","subj":"T36613","obj":"T59179"},{"id":"R2541","pred":"arg2Of","subj":"T50396","obj":"T59179"},{"id":"R80186","pred":"arg2Of","subj":"T36613","obj":"T83510"},{"id":"R38806","pred":"arg1Of","subj":"T4240","obj":"T2183"},{"id":"R9880","pred":"arg1Of","subj":"T4240","obj":"T18383"},{"id":"R77420","pred":"arg2Of","subj":"T12131","obj":"T18383"},{"id":"R60391","pred":"arg1Of","subj":"T12131","obj":"T99269"},{"id":"R95922","pred":"arg1Of","subj":"T4240","obj":"T36613"},{"id":"R85485","pred":"arg2Of","subj":"T39579","obj":"T36613"},{"id":"R67798","pred":"arg1Of","subj":"T39579","obj":"T91622"},{"id":"R82541","pred":"arg1Of","subj":"T39579","obj":"T72559"},{"id":"R48725","pred":"arg2Of","subj":"T31686","obj":"T72559"},{"id":"R83808","pred":"arg1Of","subj":"T55829","obj":"T20580"},{"id":"R25087","pred":"arg2Of","subj":"T23341","obj":"T20580"},{"id":"R66336","pred":"arg1Of","subj":"T23341","obj":"T23846"},{"id":"R9016","pred":"arg2Of","subj":"T68740","obj":"T23846"},{"id":"R27767","pred":"arg1Of","subj":"T68740","obj":"T23496"},{"id":"R79010","pred":"arg1Of","subj":"T55829","obj":"T74721"},{"id":"R49789","pred":"arg1Of","subj":"T26913","obj":"T3255"},{"id":"R98083","pred":"arg1Of","subj":"T26913","obj":"T47829"},{"id":"R36266","pred":"arg1Of","subj":"T26913","obj":"T16466"},{"id":"R42101","pred":"arg1Of","subj":"T26913","obj":"T47643"},{"id":"R24725","pred":"arg1Of","subj":"T26913","obj":"T10299"},{"id":"R12375","pred":"arg2Of","subj":"T2642","obj":"T10299"},{"id":"R19448","pred":"arg1Of","subj":"T2642","obj":"T19318"},{"id":"R23710","pred":"arg1Of","subj":"T2642","obj":"T76428"},{"id":"R34529","pred":"arg1Of","subj":"T10299","obj":"T59448"},{"id":"R60141","pred":"arg2Of","subj":"T49967","obj":"T59448"},{"id":"R2931","pred":"arg1Of","subj":"T49967","obj":"T2352"},{"id":"R3822","pred":"arg2Of","subj":"T57517","obj":"T2352"},{"id":"R20207","pred":"arg1Of","subj":"T57517","obj":"T3020"},{"id":"R30096","pred":"arg1Of","subj":"T26913","obj":"T55829"},{"id":"R66579","pred":"arg2Of","subj":"T26456","obj":"T55829"},{"id":"R14919","pred":"arg1Of","subj":"T26456","obj":"T39392"},{"id":"R49718","pred":"arg1Of","subj":"T26913","obj":"T26456"},{"id":"R70070","pred":"arg1Of","subj":"T52249","obj":"T13795"},{"id":"R68506","pred":"arg2Of","subj":"T35357","obj":"T13795"},{"id":"R94657","pred":"arg1Of","subj":"T35357","obj":"T15563"},{"id":"R49835","pred":"arg1Of","subj":"T35357","obj":"T53693"},{"id":"R88768","pred":"arg1Of","subj":"T35357","obj":"T16756"},{"id":"R7103","pred":"arg2Of","subj":"T58859","obj":"T16756"},{"id":"R65241","pred":"arg1Of","subj":"T81904","obj":"T53621"},{"id":"R80896","pred":"arg1Of","subj":"T81904","obj":"T11852"},{"id":"R48507","pred":"arg1Of","subj":"T81904","obj":"T58859"},{"id":"R74990","pred":"arg2Of","subj":"T39367","obj":"T58859"},{"id":"R57531","pred":"arg1Of","subj":"T39367","obj":"T35171"},{"id":"R26123","pred":"arg1Of","subj":"T16756","obj":"T20306"},{"id":"R11811","pred":"arg2Of","subj":"T44856","obj":"T20306"},{"id":"R59105","pred":"arg1Of","subj":"T44856","obj":"T63670"},{"id":"R40530","pred":"arg1Of","subj":"T71428","obj":"T15733"},{"id":"R29016","pred":"modOf","subj":"T16756","obj":"T15733"},{"id":"R33735","pred":"arg2Of","subj":"T64138","obj":"T71428"},{"id":"R2474","pred":"arg1Of","subj":"T64138","obj":"T29390"},{"id":"R56840","pred":"arg1Of","subj":"T64138","obj":"T54708"},{"id":"R22469","pred":"arg1Of","subj":"T64138","obj":"T21425"},{"id":"R7749","pred":"arg2Of","subj":"T78861","obj":"T21425"},{"id":"R22133","pred":"arg1Of","subj":"T78861","obj":"T75685"}],"text":"A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T75","span":{"begin":83,"end":89},"obj":"Body_part"},{"id":"T76","span":{"begin":103,"end":111},"obj":"Body_part"},{"id":"T77","span":{"begin":357,"end":367},"obj":"Body_part"},{"id":"T78","span":{"begin":435,"end":441},"obj":"Body_part"},{"id":"T79","span":{"begin":485,"end":488},"obj":"Body_part"},{"id":"T80","span":{"begin":533,"end":539},"obj":"Body_part"},{"id":"T81","span":{"begin":619,"end":625},"obj":"Body_part"},{"id":"T82","span":{"begin":725,"end":731},"obj":"Body_part"}],"attributes":[{"id":"A76","pred":"fma_id","subj":"T76","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A78","pred":"fma_id","subj":"T78","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A77","pred":"fma_id","subj":"T77","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A79","pred":"fma_id","subj":"T79","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A80","pred":"fma_id","subj":"T80","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A81","pred":"fma_id","subj":"T81","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A75","pred":"fma_id","subj":"T75","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A82","pred":"fma_id","subj":"T82","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T64","span":{"begin":255,"end":263},"obj":"Disease"},{"id":"T65","span":{"begin":475,"end":484},"obj":"Disease"},{"id":"T66","span":{"begin":547,"end":556},"obj":"Disease"}],"attributes":[{"id":"A64","pred":"mondo_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A65","pred":"mondo_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A66","pred":"mondo_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sentences","denotations":[{"id":"T92","span":{"begin":0,"end":264},"obj":"Sentence"},{"id":"T93","span":{"begin":265,"end":396},"obj":"Sentence"},{"id":"T94","span":{"begin":397,"end":566},"obj":"Sentence"},{"id":"T95","span":{"begin":567,"end":732},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}